NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) — The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Macquarie Infrastructure Corporation (NYSE:MIC)
Lead Plaintiff Deadline: June 25, 2018
Class Period: February 22, 2016 and February 21, 2018
The complaint alleges that the Company and its executives violated federal securities laws by failing to disclose the shifting commodity demands and material risks facing its International-Matex Tank Terminals (“IMTT”) business segment.
Get additional information: http://www.wongesq.com/pslra-c/macquarie-infrastructure-corporation?wire=3.
InnerWorkings, Inc. (NASDAQ:INWK)
Lead Plaintiff Deadline: July 9, 2018
Class Period: August 11, 2015 and May 7, 2018
The complaint alleges that InnerWorkings’ financial statements for the fiscal years ending December 31, 2015, 2016, and 2017, as well as all interim periods, contained errors that required restating; and as a result, InnerWorkings’ public statements were materially false and misleading at all relevant times.
Get additional information: http://www.wongesq.com/pslra-c/innerworkings-inc-2?wire=3.
Micro Focus International plc (NYSE:MFGP)
Lead Plaintiff Deadline: July 23, 2018
Class Period: September 1, 2017 and March 19, 2018; pursuant to the August 4 and August 22, 2017 Prospectuses
The complaint alleges that the Registration Statement and Prospectus filed for the Company’s Initial Public Offering contained materially false and misleading information and/or failed to disclose material information, and that Micro Focus made materially false and misleading statements and/or failed to disclose material information throughout the class period.
Get additional information: http://www.wongesq.com/pslra-c/micro-focus-international-plc?wire=3.
Recro Pharma, Inc. (NASDAQ:REPH)
Lead Plaintiff Deadline: July 30, 2018
Class Period: July 31, 2017 and May 23, 2018
The complaint alleges that the Company’s lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (“FDA”) approval; and as a result, Recro Pharma’s public statements were materially false and misleading at all relevant times.
Get additional information: http://www.wongesq.com/pslra-c/recro-pharma-inc-2?wire=3.
Aegean Marine Petroleum Network Inc. (NYSE:ANW)
Lead Plaintiff Deadline: August 6, 2018
Class Period: April 28, 2016 and June 4, 2018
The complaint alleges that Aegean had improperly accounted for an approximate $200 million of accounts receivable as of December 31, 2017; Aegean failed to maintain effective internal control over financial reporting; and as a result of the foregoing, Defendants’ statements about Aegean’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Get additional information: http://www.wongesq.com/pslra-c/aegean-marine-petroleum-network-inc?wire=3.
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit the websites provided.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002